You are here

Urol Clin North Am DOI:10.1016/j.ucl.2012.07.005

Moving toward personalized medicine in castration-resistant prostate cancer.

Publication TypeJournal Article
Year of Publication2012
AuthorsVan Allen, EM, Pomerantz, M
JournalUrol Clin North Am
Volume39
Issue4
Pages483-90
Date Published2012 Nov
ISSN1558-318X
KeywordsAndrogens, Antineoplastic Agents, Carrier Proteins, Disease Progression, Humans, Immunotherapy, Male, Neoplasms, Hormone-Dependent, Precision Medicine, Prostatic Neoplasms, Receptors, Androgen
Abstract

Recent advances in research technologies have allowed improved molecular characterization of castration-resistant prostate cancer (CRPC). These efforts hold promise for development of therapies that target alterations unique to an individual patient's prostate cancer. Targets include androgens and the androgen receptor pathway, pathways associated with hormone-resistant disease, and the immune system. In aggregate, this will allow physicians to choose treatments based on a particular tumor profile. As these approaches are developed, CRPC treatment is becoming an example of truly personalized medicine.

URLhttp://linkinghub.elsevier.com/retrieve/pii/S0094-0143(12)00053-5
DOI10.1016/j.ucl.2012.07.005
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/23084525?dopt=Abstract

Alternate JournalUrol. Clin. North Am.
PubMed ID23084525